420 related articles for article (PubMed ID: 19059635)
1. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer.
Richel O; Zum Vörde Sive Vörding PJ; Rietbroek R; Van der Velden J; Van Dijk JD; Schilthuis MS; Westermann AM
Gynecol Oncol; 2004 Dec; 95(3):680-5. PubMed ID: 15581981
[TBL] [Abstract][Full Text] [Related]
3. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
[TBL] [Abstract][Full Text] [Related]
4. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
[TBL] [Abstract][Full Text] [Related]
5. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
Jones E; Alvarez Secord A; Prosnitz LR; Samulski TV; Oleson JR; Berchuck A; Clarke-Pearson D; Soper J; Dewhirst MW; Vujaskovic Z
Int J Hyperthermia; 2006 Mar; 22(2):161-72. PubMed ID: 16754599
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
7. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
[TBL] [Abstract][Full Text] [Related]
8. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
[TBL] [Abstract][Full Text] [Related]
9. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
10. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
11. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.
Beddoe AM; Dottino PR; Cohen CJ
Mt Sinai J Med; 1993 Sep; 60(4):311-6. PubMed ID: 8232377
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
Alvarez Secord A; Jones EL; Hahn CA; Petros WP; Yu D; Havrilesky LJ; Soper JT; Berchuck A; Spasojevic I; Clarke-Pearson DL; Prosnitz LR; Dewhirst MW
Int J Hyperthermia; 2005 Jun; 21(4):333-47. PubMed ID: 16019859
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
[TBL] [Abstract][Full Text] [Related]
15. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
16. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer.
Westermann AM; Grosen EA; Katschinski DM; Jäger D; Rietbroek R; Schink JC; Tiggelaar CL; Jäger E; Zum Vörde sive Vörding P; Neuman A; Knuth A; Van Dijk JD; Wiedemann GJ; Robins HI
Eur J Cancer; 2001 Jun; 37(9):1111-7. PubMed ID: 11378341
[TBL] [Abstract][Full Text] [Related]
19. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
Misawa A; Yasuda M
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
[TBL] [Abstract][Full Text] [Related]
20. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
